{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:47Z","timestamp":1786649987546,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12325-022-02155-9","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T03:24:11Z","timestamp":1652671451000},"page":"3214-3224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan\u00ae Databases"],"prefix":"10.1007","volume":"39","author":[{"given":"Craig","family":"Leonardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Malatestinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Eastman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwangi J.","family":"Murage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey Kar-Chan","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"issue":"9997","key":"2155_CR1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Schon MP. Psoriasis Lancet. 2015;386(9997):983\u201394.","journal-title":"Psoriasis Lancet"},{"issue":"13","key":"2155_CR2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"2155_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2155_CR4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2155_CR5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","volume":"167","author":"AB Gottlieb","year":"2012","unstructured":"Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649\u201357.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2155_CR6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2340\/00015555-0511","volume":"88","author":"C Zachariae","year":"2008","unstructured":"Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88(5):495\u2013501.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"2155_CR7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaad.2014.08.003","volume":"71","author":"J Takeshita","year":"2014","unstructured":"Takeshita J, Wang S, Shin DB, Callis Duffin K, Krueger GG, Kalb RE, et al. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. J Am Acad Dermatol. 2014;71(6):1167\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2155_CR8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health."},{"issue":"5","key":"2155_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"issue":"6","key":"2155_CR10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/09546634.2018.1476652","volume":"30","author":"W Wang","year":"2019","unstructured":"Wang W, Qiu Y, Zhao F, Zhang F. Poor medication adherence in patients with psoriasis and a successful intervention. J Dermatolog Treat. 2019;30(6):525\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"2155_CR11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1744666X.2018.1427065","volume":"14","author":"L Seale","year":"2018","unstructured":"Seale L, Cardwell LA, Feldman SR. Adherence to biologics in patients with psoriasis. Expert Rev Clin Immunol. 2018;14(2):155\u201361.","journal-title":"Expert Rev Clin Immunol"},{"key":"2155_CR12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2147\/PPA.S233993","volume":"14","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, et al. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab. Patient Prefer Adherence. 2020;14:517\u201327.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"2155_CR13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaad.2019.11.015","volume":"82","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2020;82(4):927\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"2155_CR14","doi-asserted-by":"crossref","unstructured":"Hendrix N, Marcum ZA, Veenstra DL. Medication persistence of targeted immunomodulators for plaque psoriasis: A retrospective analysis using a US claims database. Pharmacoepidemiol Drug Saf. 2020;29(6):675\u201383.","DOI":"10.1002\/pds.5021"},{"issue":"2","key":"2155_CR15","first-page":"320","volume":"179","author":"KA Papp","year":"2018","unstructured":"Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179(2):320\u20138.","journal-title":"Br J Dermatol"},{"issue":"7","key":"2155_CR16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","volume":"30","author":"A Menter","year":"2016","unstructured":"Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148\u201358.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2155_CR17","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the british association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015;135(11):2632\u201340.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2155_CR18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1468-3083.2011.04325.x","volume":"26","author":"V Ruiz Salas","year":"2012","unstructured":"Ruiz Salas V, Puig L, Alomar A. Ustekinumab in clinical practice: response depends on dose and previous treatment. J Eur Acad Dermatol Venereol. 2012;26(4):508\u201313.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02155-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:06:30Z","timestamp":1656443190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2155"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02155-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}